1,721,284 research outputs found
Cogan's Syndrome
No full textCore Messages
• Cogan’s syndrome (CS) is a rare disease,
probably of organ-specifi c autoimmunity,
likely triggered by an
infection.
• Typical CS is characterized by nonsyphilitic
interstitial keratitis associated with
middle ear symptoms with progressive
hearing loss.
• CS becomes atypical in case of different
type of eye and/or ear involvement
or when the interval between the
initial manifestations is longer than
2 years.
• Systemic corticosteroids therapy is the
most effective treatment especially in
the presence of compromised auditory
acuity.
• The immediate steroid treatment can
prevent hearing loss.
• In case of failure or insuffi cient response
to corticosteroids, immunomodulatory
agents can be useful
Prognostic value of a combined panel of soluble and genetic biomarkers in patients with early arthritis
No full textAt present, to help clinical decision-making, a model that full successfully predicts UA outcome, easily assessable in clinical practice, is lacking.
However, in order to address the goal of early identification of UA patients with high risk to develop RA, prediction model has been proposed.
All these models estimate the frequency of progression to RA related to the calculated score attributed to defined clinical and laboratory parameter.
Up to now, in all proposed models, the assessment of soluble biomarkes included are limited to RF and anti-CCP antibody evaluation.
Model proposed by Van der Helm appears to be the main algorithm that has been extensively applied in different cohort of UA patients in order to
evaluated the accuracy in outcome prediction (Van der Helm-Van Mil AHN et al, Arthritis Rheum, 2007: Van der Helm-Van Mil AHN et al, Arthritis
Rheum, 2008). This algorithm appear to have a good accuracy for predicting outcome of UA patients presenting respectively low (=/<6.0) (91% did
not develop RA) and high (=/>8) score (84% develop RA). Unfortunately, this model appear to be inadequate in estimating the risk in 25% of UA
with an intermediate score. More recently, in 2010, the American College of Rheumatology (ACR) and the European League Against Rheumatism
(EULAR) developed new criteria for facilitating the early identification of UA patient with highest probability to develop persistent or erosive RA.
Recent studies, aiming to evaluate the diagnostic performance of ACR/EULAR 2010 criteria, showed good predictive value for UA patient scored
=/>6, overlapping accuracy of Van der Helm algorithm (Alves C et al., Ann Rheum Dis, 2011; Cader MZ, Ann Rheum Dis, 2011). On the other
hand, in these cohorts of patient a relevant rate of patients who needed to be treated during follow-up, did not fulfill the ACR/EULAR 2010 criteria at
baseline. Thus, misclassification may be a relevant issue when treatment decision are taken according to this algorithm.
These evidence underline that predicting power improvement of clinical useful model, easily assessable in clinical practice, is greatly needed.
ACR/EULAR working group for defining 2010 classification criteria stated that genetic, proteomic, serological or imaging biomarkers that provide a
more robust basis for risk stratification will be considered for a modification or amendment of the 2010 criteria.
To reach this goal, data concerning multiple evaluation of a large set of molecules in UA patients are needed.
Therefore, evaluation of a composite (genetic and soluble) biomarker profile in a cohort of recent onset UA patients (prospectively assessed),
utilizing multiplex-detection technology approach, appear to be original and innovative because:
- allow to analyze a vast number of candidate biomarkers
- may identify a reliable soluble biomarker profile in recent onset UA patients in relationship to clinical outcome
- may define the genetic network of epistatic interaction that underlie the susceptibility to develop RA in early UA patients.
- may add power in predicting early UA outcome comparing to prognostic model currently followed in clinical practice
Combined detection of multiple indicators may define a molecular signature that allows the simultaneously identification of diagnostic/prognostic
features of individuals patients, thus leading forward to the practice of personalized medicine
sj-docx-1-eso-10.1177_23969873231190431 – Supplemental material for European Stroke Organisation (ESO) guidelines on Primary Angiitis of the Central Nervous System (PACNS)
No full textSupplemental material, sj-docx-1-eso-10.1177_23969873231190431 for European Stroke Organisation (ESO) guidelines on Primary Angiitis of the Central Nervous System (PACNS) by Rosario Pascarella, Katherina Antonenko, Grégoire Boulouis, Hubert De Boysson, Caterina Giannini, Mirjam R Heldner, Odysseas Kargiotis, Thanh N Nguyen, Claire M Rice, Carlo Salvarani, Antje Schmidt-Pogoda, Daniel Strbian, Salman Hussain and Marialuisa Zedde in European Stroke Journal</p
Going Beyond Counting First Authors in Author Co-citation Analysis
Full text linkThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
Variations on the Author
Full text link“Variations on the Author” discusses two of Eduardo Coutinho’s recent films (Um Dia na Vida, from 2010, and Últimas Conversas, posthumously released in 2015) and their contribution to the general question of documentary authorship. The director’s filmography is characterized by a consistent yet self-effacing form of authorial self-inscription: Coutinho often features as an interviewer that rather than express opinions propels discourses; an interviewer that is good at listening. This mode of self-inscription characterizes him as an author who is not expressive but who is nonetheless markedly present on the screen. In Um Dia na Vida, however, Coutinho is completely absent form the image, while Últimas Conversas, on the contrary, includes a confessional prologue that moves the director from the margins to the center of his films. This article examines the ways in which these works stand out in the filmography of a director who offers new insights into the notion of cinematic authorship
Appropriate Similarity Measures for Author Cocitation Analysis
Full text linkWe provide a number of new insights into the methodological discussion about author cocitation analysis. We first argue that the use of the Pearson correlation for measuring the similarity between authors’ cocitation profiles is not very satisfactory. We then discuss what kind of similarity measures may be used as an alternative to the Pearson correlation. We consider three similarity measures in particular. One is the well-known cosine. The other two similarity measures have not been used before in the bibliometric literature. Finally, we show by means of an example that our findings have a high practical relevance.information science;Pearson correlation;cosine;similarity measure;author cocitation analysis
sj-doc-2-tab-10.1177_1759720X221090310 – Supplemental material for Effectiveness and safety of secukinumab in axial spondyloarthritis: a 24-month prospective, multicenter real-life study
No full textSupplemental material, sj-doc-2-tab-10.1177_1759720X221090310 for Effectiveness and safety of secukinumab in axial spondyloarthritis: a 24-month prospective, multicenter real-life study by Roberta Ramonda, Mariagrazia Lorenzin, Maria Sole Chimenti, Salvatore D’Angelo, Antonio Marchesoni, Carlo Salvarani, Ennio Lubrano, Luisa Costa, Ylenia Dal Bosco, Elena Fracassi, Augusta Ortolan, Mario Ferraioli, Antonio Carriero, Elisa Visalli, Riccardo Bixio, Francesca Desiati, Alberto Bergamini, Elisa Pedrollo, Andrea Doria, Rosario Foti and Antonio Carletto in Therapeutic Advances in Musculoskeletal Disease</p
Dispelling the Myths Behind First-author Citation Counts
Full text linkWe conducted a full-scale evaluative citation analysis study of scholars in the XML research field to explore just how different from each other author rankings resulting from different citation counting methods actually are, and to demonstrate the capability of emerging data and tools on the Web in supporting more realistic citation counting methods. Our results contest some common arguments for the continued
use of first-author citation counts in the evaluation of scholars, such as high correlations between author rankings by first-author citation counts and other citation
counting methods, and high costs of using more realistic citation counting methods that are not well-supported by the ISI databases. It is argued that increasingly available digital full text research papers make it possible for citation analysis studies to go beyond what the ISI databases have directly supported and to employ more
sophisticated methods
sj-docx-1-tab-10.1177_1759720X221090310 – Supplemental material for Effectiveness and safety of secukinumab in axial spondyloarthritis: a 24-month prospective, multicenter real-life study
No full textSupplemental material, sj-docx-1-tab-10.1177_1759720X221090310 for Effectiveness and safety of secukinumab in axial spondyloarthritis: a 24-month prospective, multicenter real-life study by Roberta Ramonda, Mariagrazia Lorenzin, Maria Sole Chimenti, Salvatore D’Angelo, Antonio Marchesoni, Carlo Salvarani, Ennio Lubrano, Luisa Costa, Ylenia Dal Bosco, Elena Fracassi, Augusta Ortolan, Mario Ferraioli, Antonio Carriero, Elisa Visalli, Riccardo Bixio, Francesca Desiati, Alberto Bergamini, Elisa Pedrollo, Andrea Doria, Rosario Foti and Antonio Carletto in Therapeutic Advances in Musculoskeletal Disease</p
- …
